Mark Jeffrey DeLong - 19 Jul 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Senior Vice President
Signature: /s/ David Watson, attorney-in-fact for Mark Delong
Issuer symbol: APLS
Transactions as of: 19 Jul 2022
Net transactions value: -$204,500
Form type: 4
Filing time: 21 Jul 2022, 16:31:25 UTC
Previous filing: 21 Jun 2022
Next filing: 28 Jul 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$77,600	+5,000	+17%	$15.52	34,250	19 Jul 2022	Direct	F1
transaction	APLS	Common Stock	Sale	$282,100	-5,000	-15%	$56.42	29,250	19 Jul 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-5,000	-14%	$0.000000	30,000	19 Jul 2022	Common Stock	5,000	$15.52	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled exercise and sale from an established 10B5-1 trading plan.
F2	This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.